Attovia Therapeutics (ATTO) SEC Filings, Aug 4, 2026

Frazier Life Sciences XI, L.P., together with related entities FHMLS XI, L.P. and FHMLS XI, L.L.C., reports a significant ownership position in Attovia Therapeutics, Inc. as ten percent owners. The group holds 1,749,192 shares of Series A-1 Preferred Stock, 1,590,175 shares of Series A-2 Preferred Stock, 1,189,940 shares of Series B Preferred Stock, 961,322 shares of Series C Preferred Stock (each series convertible into Common Stock at an exercise price of $0.0000 per share and automatically converting into the same number of Common shares upon closing of the initial public offering), plus 75,349 shares of Common Stock held directly.